Roman Ivanov is Vice President, R&D in biopharmaceutical company BIOCAD. He is responsible for product development and regulatory affairs.
Roman graduated from Ural State Medical Academy in Russia. Prior to joining BIOCAD, Roman conducted scientific research in the field of molecular immunology at the Hematology Department of Utrecht University Medical Centre in the Netherlands.
He is an author of multiple scientific publications in international peer-reviewed journals. Dr. Ivanov was in charge of clinical development and registration of the first Russian biosimilar granulocyte colony stimulating factor and the first Russian biosimilar monoclonal antibody Acellbia (rituximab). Currently he supervises clinical development of 7 other biosimilar candidates as well as preclinical studies of 5 innovative biological medicines developed by BIOCAD.